Arachidonate Lipoxygenase Products and Psoriasis

  • Richard D. Camp
  • Malcolm W. Greaves
  • Robert M. Barr
Part of the GWUMC Department of Biochemistry Annual Spring Symposia book series (GWUN)


Psoriasis is a common skin disease that, in many cases, appears to be genetically determined. Lesional skin is characterized by epidermal proliferation and inflammatory changes, of which intraepidermal neutrophil infiltration is a consistent finding and one of the earliest abnormalities seen in developing lesions (Chowaniec et al., 1981). Psoriasis may manifest clinically in various forms, of which the chronic, stable, scaly plaque type is the most common. However, the inflammatory changes predominate in some patients, and in generalized pustular psoriasis, an uncommon form of the disease, intraepidermal neutrophil microabscesses are the major pathological feature (Baker and Wilkinson, 1979). These findings suggest that the production of neutrophil chemoattractants by the epidermis may be important in the pathogenesis of psoriasis.


Arachidonic Acid Psoriatic Skin Psoriatic Lesion Lipoxygenase Product Chamber Fluid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allen, B.R., and Littlewood, S.M., 1982, Benoxaprofen: Effect on cutaneous lesions in psoriasis, Br. Med. J. 285:1241.CrossRefGoogle Scholar
  2. Baker, H., and Wilkinson, D. S., 1979, Psoriasis, in: Textbook of Dermatology, Vol. II (A. Rook, D. S. Wilkinson, and F. J. G. Ebling, eds.), Blackwell, Oxford, pp. 1315–1359.Google Scholar
  3. Barr, R.M., Wong, E., Mallet, A.I., Olins, L.A., and Greaves, M.W., 1984, The analysis of arachidonic acid metabolites in normal, uninvolved and lesional psoriatic skin, Prostaglandins 28:57–66.PubMedCrossRefGoogle Scholar
  4. Bisgaard, H., Kristensen, J., and Sondergaard, J., 1982, The effect of leukotriene C4 and D4 on cutaneous blood flow in humans, Prostaglandins 23:797–801.PubMedCrossRefGoogle Scholar
  5. Brain, S.D., Camp, R.D.R., Dowd, P.M., Kobza Black, A., Woollard, P.M., Mallet, A.I., and Greaves, M.W., 1982a, Psoriasis and leukotriene B4, Lancet 2:762–763.PubMedCrossRefGoogle Scholar
  6. Brain, S.D., Camp, R.D.R., Leigh, I.M., and Ford-Hutchinson, A.W., 1982b, The synthesis of leukotriene B4-like material by cultured human keratinocytes, J. Invest. Dermatol. 78:328.Google Scholar
  7. Brain, S. D., Camp, R. D. R., Dowd, P. M., Kobza Black, A., Woollard, P. M., Mallet, A. I., and Greaves, M. W., 1983, Release of leukotriene B4 (LTB4) and monohydroxyeicosatetraenoic acids (HETEs) from the involved skin of patients with psoriasis, in: Leukotrienes and Other Lipoxygenese Products (P. J. Piper, ed.), John Wiley & Sons, Chichester, pp. 248–254.Google Scholar
  8. Brain, S., Camp, R., Dowd, P., Kobza Black, A., and Greaves, M., 1984a, The release of leukotriene B4 like material in biologically active amounts from the lesional skin of patients with psoriasis, J. Invest. Dermatol. 83:70–73.PubMedCrossRefGoogle Scholar
  9. Brain, S.D., Camp, R.D.R., Cunningham, F.M., Dowd, P.M., Greaves, M.W., and Kobza Black, A., 1984b, Leukotriene B4-like material in scale of psoriatic lesions, Br. J. Pharmacol. 83:313–317.PubMedCrossRefGoogle Scholar
  10. Brain, S. D., Camp, R. D. R., Charleson, S., Dowd, P. M., Ford-Hutchinson, A. W., Greaves, M. W., and Kobza Black, A., 1984c, The release of LTC4-like material from the involved lesional skin in psoriasis, Br. J. Clin. Pharmacol. 17:650P.Google Scholar
  11. Brain, S. D., Camp, R. D. R., Kobza Black, A., Dowd, P. M., Greaves, M. W., Ford-Hutchinson, A. W., and Charleson, S., 1985, Leukotrienes C4 and D4 in psoriatic lesions, Prostaglandins (in press).Google Scholar
  12. Bray, M.A., 1984, Retinoids are potent inhibitors of the generation of rat leukocyte leukotriene B4-like activity in vitro, Eur. J. Pharmacol. 98:61–67.PubMedCrossRefGoogle Scholar
  13. Camp, R.D.R., Mallet, A.I., Woollard, P.M., Brain, S.D., Kobza Black, A., and Greaves, M.W., 1983a, The identification of hydroxy fatty acids in psoriatic skin, Prostaglandins 26:431–448.PubMedCrossRefGoogle Scholar
  14. Camp, R.D.R., Coutts, A.A., Greaves, M.W., Kay, A.B., and Walport, M.J., 1983b, Responses of human skin to intradermal injection of leukotrienes C4, D4, and B4, Br. J. Pharmacol. 80:497–502.PubMedCrossRefGoogle Scholar
  15. Camp, R.D.R., Russell Jones, R., Brain, S., Woollard, P., and Greaves, M., 1984, Production of intraepidermal microabscesses by topical application of leukotriene B4, J. Invest. Dermatol. 82:202–204.PubMedCrossRefGoogle Scholar
  16. Chowaniec, O., Jablonska, S., Beutner, E.H., Proniewska, M., Jarzabek-Chorzelska, M., and Rzesa, G., 1981, Earliest clinical and histological changes in psoriasis, Dermatologica 163:42–51.PubMedCrossRefGoogle Scholar
  17. Dowd, P.M., Woollard, P.M., Kobza Black, A., Camp, R.D.R., and Greaves, M.W., 1983, The effect of intradermal infusions of 12-hydroxyeicosatetraenoic acid (12-HETE) in normal human skin, Br. J. Dermatol. 109:693–694.Google Scholar
  18. Dowd, P. M., Kobza Black, A., Woollard, P., Camp, R. D., and Greaves, M. W., 1984, The in vivoproperties of 12-hydroxyeicosatetraenoic acid (12-HETE) in normal skin, J. Invest. Dermatol. 82:413–414.Google Scholar
  19. Fincham, N., and Camp, R., 1984, Monohydroxy fatty acids in skin may modulate 5-lipoxygenase activity, J. Invest. Dermatol. 82:401.Google Scholar
  20. Grabbe, J., Czarnetzki, B.M., and Mardin, M., 1984, Release of lipoxygenase products of arachidonic acid from freshly isolated human keratinocytes, Arch. Dermatol. Res. 276:128–130.PubMedCrossRefGoogle Scholar
  21. Hammarström, S., Hamberg, M., Samuelsson, B., Duell, E.A., Stawiski, M., and Voorhees, J.J., 1975, Increased concentrations of nonesterified arachidonic acid, 12L-hydroxy-5,8,10,14-eico-satetraenoic acid, prostaglandin E2 and prostaglandin F2in epidermis of psoriasis, Proc. Natl. Acad. Sci. U.S.A. 72:5130–5134.PubMedCrossRefGoogle Scholar
  22. Hammarström, S., Hamberg, M., Duell, E.A., Stawiski, M.A., Anderson, T.F., and Voorhees, J.J., 1977, Glucocorticoid in inflammatory proliferative skin disease reduces arachidonic and hydroxyeicosatetraenoic acids, Science 197:994–996.PubMedCrossRefGoogle Scholar
  23. Hammarström, S., Lindgren, J.A., Marcelo, C, Duell, E.A., Anderson, T.F., and Voorhees, J.J., 1979, Arachidonic acid transformations in normal and psoriatic skin, J. Invest. Dermatol. 73:180–183.PubMedCrossRefGoogle Scholar
  24. Klemp, P., and Staberg, B., 1983, Cutaneous blood flow in psoriasis, J. Invest. Dermatol. 81:503–506.PubMedCrossRefGoogle Scholar
  25. Kragballe, K., and Herlin, T., 1983, Benoxaprofen improves psoriasis, Arch. Dermatol. 119:548–552.PubMedCrossRefGoogle Scholar
  26. Luger, T.A., Charon, J.A., Colot, M., Micksche, M., and Oppenheim, J.J., 1983, Chemotactic properties of partially purified human epidermal cell derived thymocyte-activating factor (ETAF) for polymorphonuclear and mononuclear cells, J. Immunol. 131:816–820.PubMedGoogle Scholar
  27. Masters, D. J., and McMillan, R. M., 1984, 5-Lipoxygenase from human leukocytes, Br. J. Pharmacol. 81:70P.Google Scholar
  28. Peck, M.J., Piper, P.J., and Williams, T.J., 1981, The effect of leukotrienes C4 and D4 on the microvasculature of guinea pig skin, Prostaglandins 21:315–321.PubMedCrossRefGoogle Scholar
  29. Smith, M.J.H., and Walker, J.R., 1980, The effects of some antirheumatic drugs on an in vitro model of human polymorphonuclear leucocyte chemotaxis, Br. J. Pharmacol. 69:473–478.PubMedCrossRefGoogle Scholar
  30. Soter, N.A., Lewis, R.A., Corey, E.J., and Austen, K.F., 1983, Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin, J. Invest. Dermatol. 80:115–119.PubMedCrossRefGoogle Scholar
  31. Tagami, H., and Ofuji, S., 1976, Leukotactic properties of soluble substances in psoriasis scale, Br. J. Dermatol. 95:1–8.PubMedCrossRefGoogle Scholar
  32. Tagami, H., and Ofuji, S., 1977, Characterisation of a leukotactic factor derived from psoriatic scale, Br. J. Dermatol. 97:509–518.PubMedCrossRefGoogle Scholar
  33. Tagami, H., Kitano, Y., Suehisa, S., Oku, T., and Yamada, M., 1982, Psoriatic leukotactic factor. Further physicochemical characterisation and effect on the epidermal cells, Arch. Dermatol. Res. 272:201–213.PubMedCrossRefGoogle Scholar
  34. Vanderhoek, J.Y., Bryant, R.W., and Bailey, J.M., 1980, Inhibition of leukotriene biosynthesis by the leukocyte product 15-hydroxy-5,8,11,13-eicosatetraenoic acid, J. Biol. Chem. 255:10064–10066.PubMedGoogle Scholar
  35. Wong, E., Barr, R. M., Brain, S. D., Olins, L. A., and Greaves, M. W., 1983, The effect of etretinate on cyclo-oxygenase and lipoxygenase products of arachidonic acid in psoriatic skin, Br. J. Dermatol. 109:703Google Scholar
  36. Wong, E., Camp, R., and Greaves, M. W., 1985, Topical application of leukotriene B4 in normal and psoriatic subjects, J. Invest. Dermatol. (in press).Google Scholar
  37. Woollard, P.M., and Mallet, A.I., 1984, A novel gas chromatographic-mass spectrometric assay for monohydroxy fatty acids, J. Chromatogr. 306:1–21.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • Richard D. Camp
    • 1
  • Malcolm W. Greaves
    • 1
  • Robert M. Barr
    • 1
  1. 1.Wellcome Laboratories for Skin PharmacologyInstitute of Dermatology, Homerton GroveLondonUK

Personalised recommendations